# Chemed Corp: Form 10-Q for the period ended Sep 30, 2014

- Company: [Chemed Corp](/companies/che.md) (CIK 19584)
- Form: 10-Q
- Filed: 2014-11-05
- Accepted by EDGAR: Nov 5, 2014, 08:35 ET
- Period: 2014-09-30
- Accession: 0001157523-14-004380
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/19584/000115752314004380/a50974295.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/19584/000115752314004380/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2014-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2014-07-01 to 2014-09-30 | $358.4m | us-gaap:SalesRevenueNet |
| Revenue | 9 months, 2014-01-01 to 2014-09-30 | $1.08bn | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months, 2014-07-01 to 2014-09-30 | $256.4m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2014-01-01 to 2014-09-30 | $771.3m | us-gaap:CostOfGoodsAndServicesSold |
| Selling, general and administrative | 3 months, 2014-07-01 to 2014-09-30 | $53.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2014-01-01 to 2014-09-30 | $162.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2014-07-01 to 2014-09-30 | $40.2m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2014-01-01 to 2014-09-30 | $118.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2014-07-01 to 2014-09-30 | $980.0k | us-gaap:InterestExpense |
| Interest expense | 9 months, 2014-01-01 to 2014-09-30 | $7.2m | us-gaap:InterestExpense |
| Income tax | 3 months, 2014-07-01 to 2014-09-30 | $15.4m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2014-01-01 to 2014-09-30 | $43.9m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2014-07-01 to 2014-09-30 | $24.6m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2014-01-01 to 2014-09-30 | $69.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2014-07-01 to 2014-09-30 | $1.39 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2014-01-01 to 2014-09-30 | $3.87 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2014-07-01 to 2014-09-30 | $1.44 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2014-01-01 to 2014-09-30 | $4.03 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2014-07-01 to 2014-09-30 | 17,627,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2014-01-01 to 2014-09-30 | 17,968,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2014-01-01 to 2014-09-30 | $51.0m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 9 months, 2014-01-01 to 2014-09-30 | $31.7m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months, 2014-01-01 to 2014-09-30 | $10.6m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 9 months, 2014-01-01 to 2014-09-30 | $99.1m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2014-09-30 | $18.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2014-09-30 | $188.7m | us-gaap:AssetsCurrent |
| Total assets | at 2014-09-30 | $869.5m | us-gaap:Assets |
| Current liabilities | at 2014-09-30 | $197.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2014-09-30 | $437.1m | us-gaap:Liabilities |
| Long-term debt | at 2014-09-30 | $153.1m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2014-09-30 | $20.4m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2014-09-30 | $432.4m | us-gaap:StockholdersEquity |
| Shares outstanding | at 2014-09-30 | 17,010,464 shares | dei:EntityCommonStockSharesOutstanding |

## Management's discussion and analysis

As filed, 55,283 characters.

### Executive Summary

We operate through our two wholly-owned subsidiaries, VITAS Healthcare Corporation and Roto-Rooter Group, Inc. VITAS focuses on hospice care that helps make terminally ill patients’ final days as comfortable as possible. Through its teams of doctors, nurses, home health aides, social workers, clergy and volunteers, VITAS provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. Roto-Rooter’s services are focused on providing plumbing and drain cleaning services to both residential and commercial customers. Through its network of company-owned branches, independent contractors and franchisees, Roto-Rooter offers plumbing and drain cleaning service to over 90% of the U.S. population.

The following is a summary of the key operating results (in thousands except per share amounts):

|  | Three months ended September 30, 2014 | 2013 | Nine months ended September 30, 2014 | 2013 |
| --- | ---: | ---: | ---: | ---: |
| Service revenues and sales | **$358,389** | $340,886 | **$1,076,871** | $1,064,725 |
| Net income | **$24,585** | $17,432 | **$69,522** | $54,318 |
| Diluted EPS | **$1.39** | $0.94 | **$3.87** | $2.89 |
| Adjusted net income | **$26,058** | $25,098 | **$76,351** | $78,470 |
| Adjusted diluted EPS | **$1.48** | $1.36 | **$4.28** | $4.17 |
| Adjusted EBITDA | **$50,946** | $49,739 | **$150,831** | $153,978 |
| Adjusted EBITDA as a % of revenue | **14.2%** | 14.6% | **14.0%** | 14.5% |

Adjusted net income, adjusted diluted EPS, earnings before interest, taxes and depreciation and amortization (“EBITDA”) and Adjusted EBITDA are not measures derived in accordance with GAAP. We provide non-GAAP measures to help readers evaluate our operating results, compare our operating performance with that of similar companies that have different capital structures and help evaluate our ability to meet future debt service, capital expenditure and working capital requirements. Our non-GAAP measures should not be considered in isolation or as a substitute for comparable measures presented in accordance with GAAP. A reconciliation of our non-GAAP measures are presented on pages 28-30.

For the three months ended September 30, 2014, the increase in consolidated service revenues and sales was driven by a 7.0% increase at Roto-Rooter and a 4.5% increase at VITAS. The increase in service revenues at Roto-Rooter was driven by an increase in a combination of price and service mix shift offset by a decrease in job count. The remaining difference relates to increases in contractor revenue and increases in our water restoration business line. Water restoration is the remediation of water and humidity damage after a flood. The increase in service revenues at VITAS was a result of Medicare reimbursement rates increasing 1.4%, a 2.8% increase in average daily census and mix shift. Consolidated net income increased 41.0% mainly as a result of lawsuit settlements in 2013 at Vitas and Roto-Rooter that did not repeat in 2014. Diluted EPS increased 47.9% as a result of the increase in net income as well as a lower number of shares outstanding. Adjusted EBITDA as a percent of revenue decreased 0.4%. See page 31 for additional VITAS operating metrics.

For the nine months ended September 30, 2014, the increase in consolidated service revenues and sales was driven by a 4.1% increase at Roto-Rooter and a 0.1% increase at VITAS. The increase in service revenues at Roto-Rooter was driven by an increase in a combination of price, and service mix shift offset by a decrease in job count. The remaining difference relates to increases in contractor revenue and increases in our water restoration business line. Consolidated net income increased 28.0% mainly as a result of lawsuit settlements in 2013 at VITAS and Roto-Rooter that did not repeat in 2014. Diluted EPS increased 33.9% as a result of the increase in net income as well as a lower number of shares outstanding. Adjusted EBITDA as a percent of revenue decreased 0.5%. See page 31 for additional VITAS operating metrics.

On April 1, 2013, Medicare reduced hospice reimbursement rates 2.0%. Effective October 1, 2013, Medicare increased the average hospice rate approximately 1.4% This effectively reduced Medicare hospice reimbursement 0.6% through the first quarter of 2014. VITAS expects its full-year 2014 revenue growth, prior to Medicare cap, to be in the range of 1.0% to 2.0%. Admissions in 2014 are estimated to increase 2.0%. Adjusted EBITDA margin, prior to Medicare cap, is estimated to be 14.5% to 15.0%. Medicare cap is estimated to be $3.6 million in 2014. Roto-Rooter expects full-year 2014 revenue growth of 4.0% to 5.0%. The revenue estimate is a result of increased job pricing of approximately 2.0%. Adjusted EBITDA margin for 2014 is estimated in the range of 19.0% to 19.5%. We anticipate that our operating income and cash flows will be sufficient to operate our businesses and meet any commitments for the foreseeable future.

-15-

### Financial Condition

### Liquidity and Capital Resources

Material changes in the balance sheet accounts from December 31, 2013 to September 30, 2014 include the following:

- A $65.9 million decrease in cash due to purchases of treasury stock and capital expenditures, partially offset by cash generated by operations.
- A $40.6 million increase in accounts receivable related to the timing of payments.
- A $15.3 million increase in accounts payable due to timing of payments.
- A $10.0 million decrease in total long-term debt as a result of net payments of outstanding debt using cash on-hand.
- A $22.5 million decrease in accrued legal due to the payment of litigation settlements.

Net cash provided by operating activities decreased $84.8 million primarily as a result of the increase in accounts receivable and a decline in accrued legal expenses. Management continually evaluates cash utilization alternatives, including share repurchase, debt repurchase, acquisitions and increased dividends to determine the most beneficial use of available capital resources.

We have issued $36.9 million in standby letters of credit as of September 30, 2014, for insurance purposes. Issued letters of credit reduce our available credit under the revolving credit agreement. As of September 30, 2014, we have approximately $238.3 million of unused lines of credit available and eligible to be drawn down under our revolving credit facility. Management believes its liquidity and sources of capital are satisfactory for the Company’s needs in the foreseeable future.

### Commitments and Contingencies

Collectively, the terms of our credit agreements require us to meet various financial covenants, to be tested quarterly. We are in compliance with all financial and other debt covenants as of September 30, 2014 and anticipate remaining in compliance throughout 2014.

The VITAS segment of the Company’s business operates in a heavily-regulated industry. As a result, the Company is subjected to inquiries and investigations by various government agencies, as well as to lawsuits, including *qui tam* actions. The following sections describe the various ongoing material lawsuits and investigations of which the Company is currently aware. It is not possible at this time for us to estimate either the timing or outcome of any of those matters, or whether any potential loss, or range of potential losses, is probable or estimable.

On January 12, 2012, a putative class action lawsuit was filed in the U.S. District Court for the Southern District of Ohio against the Company, David Williams, and Timothy O’Toole, *In re Chemed Corp. Securities Litigation*, Civil Action No. 1:12-cv-28 (S.D. Ohio). As the Company has previously disclosed, on February 6, 2014, the Plaintiffs, on behalf of a putative class of purchasers of Chemed Capital Stock between February 15, 2010 and May 2, 2013, inclusive, executed a stipulation of settlement with Defendants. That settlement received final court approval on July 15, 2014, resulting in the dismissal of the case. No appeal of that judgment has since been filed. Defendants agreed to enter into this settlement in order to eliminate the burden, expense and distraction of further litigation.

In June 2011, the U.S. Attorney provided the Company with a partially unsealed *qui tam* complaint filed under seal in the U.S. District Court for the Western District of Texas, *United States, et al. ex rel. Urick v. VITAS HME Solutions, Inc. et al.*, 5:08-cv-0663 (“*Urick”).* The U.S. Attorney filed a notice in May 2012 stating that it had decided not to intervene in the case at that time but indicating that it continues to investigate the allegations. In June 2012, the complaint was unsealed. The complaint asserts violations of the federal False Claims Act and the Texas Medicaid Fraud Prevention Act based on allegations of a conspiracy to submit to Medicare and Medicaid false claims involving hospice services for ineligible patients, unnecessary medical supplies, failing to satisfy certain prerequisites for payment, and altering patient records, including backdating patient revocations. The suit was brought by Barbara Urick, a registered nurse in VITAS’s San Antonio program, against VITAS, certain of its affiliates, and several former VITAS employees, including physicians Justo Cisneros and Antonio Cavasos and nurses Sally Schwenk, Diane Anest, and Edith Reed. In September 2012 and July 2013, the plaintiff dismissed all claims against the individual defendants. The complaint was served on the VITAS entities on April 12, 2013.

Also in June 2011, the U.S. Attorney provided the Company with a partially unsealed *qui tam* complaint filed under seal in the U.S. District Court for the Northern District of Illinois, *United States, et al. ex rel. Spottiswood v. Chemed Corp.*, 1:07-cv-4566 (“*Spottiswood”).* In April 2012, the complaint was unsealed. The U.S. Attorney and Attorney General for the State of Illinois filed notices in April and May 2012, respectively, stating that they had decided not to intervene in the case at that time but indicating that they continue to investigate the allegations. Plaintiff filed an amended complaint in November 2012. The complaint asserts violations of the federal False Claims Act and the Illinois Whistleblower Reward and Protection Act based on allegations that VITAS fraudulently billed Medicare and Medicaid for providing unwarranted continuous care services. The suit was brought by Laura Spottiswood, a former part-time pool registered nurse at VITAS, against Chemed, VITAS, and a VITAS affiliate. The complaint was served on the defendants on April 12, 2013. On May 29 and June 4, 2013, respectively, the Court granted the government’s motion to partially intervene in *Spottiswood* and in *Urick* on the allegations that VITAS submitted or caused to be submitted false or fraudulent claims for continuous care and routine home care on behalf of certain ineligible Medicare beneficiaries. The Court also transferred them to the U.S. District Court for the Western District of Missouri under docket Nos. 4:13-cv-505 and 4:13-cv-563, respectively.

-16-

On May 2, 2013, the government filed a False Claims Act complaint against the Company and certain of its hospice-related subsidiaries in the U.S. District Court for the Western District of Missouri, *United States v. VITAS Hospice Services, LLC, et al.*, No. 4:13-cv-00449-BCW (the “2013 Action”). Prior to that date, the Company received various subpoenas from the U.S. Department of Justice and OIG that have been previously disclosed. The 2013 Action alleges that, since at least 2002, VITAS, and since 2004, the Company, submitted or caused the submission of false claims to the Medicare program by (a) billing Medicare for continuous home care services when the patients were not eligible, the services were not provided, or the medical care was inappropriate, and (b) billing Medicare for patients who were not eligible for the Medicare hospice benefit because they did not have a life expectancy of six months or less if their illnesses ran their normal course. This complaint seeks treble damages, statutory penalties, and the costs of the action, plus interest. On August 1, 2013, the government filed its First Amended Complaint in the 2013 Action. The First Amended Complaint changed and supplemented some of the allegations, but did not otherwise expand the causes of action or the nature of the relief sought against VITAS. The defendants filed a motion to dismiss on September 24, 2013. The Court denied the motion, except to the extent that claims were filed before July 24, 2002, on September 30, 2014.

On May 6, 2013, the U.S. District Court for the Western District of Missouri, at the request of the government, unsealed a *qui tam* complaint against VITAS and VITAS Healthcare Corporation of California, *United States ex rel. Charles Gonzales v. VITAS Healthcare Corporation, et al.,* CV 12-0761-R (“*Gonzales”).* The case was transferred from the Central District of California to the Western District of Missouri under docket No. 4:13-cv-344. The government partially intervened in *Gonzales.* The *Gonzales* complaint alleges that VITAS’ Los Angeles program falsely certified and recertified patients as eligible for the Medicare Hospice Benefit. It alleges violations of the False Claims Act and seeks treble damages, civil penalties, recovery of costs, attorneys’ fees and expenses, and pre- and post-judgment interest.

On September 25, 2013, the Court granted a joint motion by the government, the relators, and VITAS to consolidate the *Spottiswood, Urick*, and *Gonzales* complaints with the 2013 Action. As a result, the First Amended Complaint will govern the consolidated federal claims brought by the United States and the relators for all purposes. The relators and VITAS have stipulated that certain non-intervened claims will not be pursued by the relators. The Spottiswood relator filed an action under the Illinois False Claims Act, *The State of Illinois ex rel. Laura Spottiswood v. Chemed Corporation*, et al., No. 14 L 2786 in the Circuit Court of Cook County, Illinois on March 6, 2014. The Court granted the parties’ joint motion to place this case on its stay calendar, pending resolution of the 2013 Action.

VITAS has also received document subpoenas in related state matters. In February 2010, VITAS received a civil investigative demand (“CID”) from the Texas Attorney General seeking documents from January 1, 2002 through the date of the CID, and interrogatory responses in connection with an investigation of possible fraudulent submission of Medicaid claims for non-qualifying patients and fraudulent shifting of costs from VITAS to the State of Texas and the United States. The CID requested similar information sought by prior Department of Justice subpoenas, including policy and procedure manuals and information concerning Medicare and Medicaid billing, patient statistics and sales and marketing practices, together with information concerning record-keeping and retention practices, and medical records concerning 117 patients. In September 2010, VITAS received a third CID from the Texas Attorney General seeking additional documents concerning business plans and results, revocation forms for certain patients, and electronic documents of 10 current and former employees. In July 2012, VITAS received an investigative subpoena from the Florida Attorney General seeking documents previously produced in the course of prior government investigations as well as, for the period January 1, 2007 through the date of production, billing records and procedures; information concerning business results, plans, and strategies; documents concerning patient eligibility for hospice care; and certain information concerning employees and their compensation.

The net costs incurred related to U.S. v. Vitas and related regulatory matters were $450,000 and a $591,000 credit for the three months ended September 30, 2014 and 2013, respectively. For the nine months ended September 30, 2014 and 2013, the net costs were $1.6 million and $1.4 million respectively.

-17-

In November 2013, two shareholder derivative lawsuits were filed against the Company’s current and former directors, as well as certain of its officers, both of which are covered by the Company’s commercial insurance. On November 6, 2013, KBC Asset Management NV filed suit in the United States District Court for the District of Delaware, *KBC Asset Management NV, derivatively on behalf of Chemed Corp. v. McNamara, et al.*, No. 13 Civ. 1854 (LPS) (D. Del.). It sued Kevin McNamara, Joel Gemunder, Patrick Grace, Thomas Hutton, Walter Krebs, Andrea Lindell, Thomas Rice, Donald Saunders, Arthur Tucker, Jr., George Walsh III, Frank Wood, Timothy O’Toole, David Williams and Ernest Mrozek, together with the Company as nominal defendant. Plaintiff alleges that since at least 2004, Chemed, through VITAS, has submitted or caused the submission of false claims to Medicare. The suit alleges a claim for breach of fiduciary duty against the individual defendants, and seeks (a) a declaration that the individual defendants breached their fiduciary duties to the Company; (b) an order requiring those defendants to pay compensatory damages, restitution and exemplary damages, in unspecified amounts, to the Company; (c) an order directing the Company to implement new policies and procedures; and (d) costs and disbursements incurred in bringing the action, including attorneys’ fees.

On November 14, 2013, Mildred A. North filed suit in the United States District Court for the Southern District of Ohio, *North, derivatively on behalf of Chemed Corp. v. Kevin McNamara, el al.*, No. 13 Civ. 833 (MDB) (S.D. Ohio). She sued Kevin McNamara, David Williams, Timothy O’Toole, Joel Gemunder, Patrick Grace, Walter Krebs, Andrea Lindell, Thomas Rice, Donald Saunders, George Walsh III, Frank Wood and Thomas Hutton, together with the Company as nominal defendant. Plaintiff alleges that, between February 2010 and the present, the individual defendants breached their fiduciary duties as officers and directors of Chemed by, among other things, (a) allegedly causing VITAS to submit improper and ineligible claims to Medicare and Medicaid; and (b) allegedly misrepresenting the state of Chemed’s internal controls. The suit alleges claims for breach of fiduciary duty, abuse of control and gross mismanagement against the individual defendants. The complaint also alleges unjust enrichment and insider trading against Messrs. McNamara, Williams and O’Toole. Plaintiff seeks (a) a declaration that the individual defendants breached their fiduciary duties to the Company; (b) an order requiring those defendants to pay compensatory damages, restitution and exemplary damages, in unspecified amounts, to the Company; (c) an order directing the Company to implement new policies and procedures; and (d) costs and disbursements incurred in bringing the action, including attorneys’ fees.

On January 29, 2014 defendants in *North* filed a motion to transfer that case to Delaware under 28 U.S.C § 1404(a). On February 12, 2014, defendants in *KBC* filed a motion to dismiss that case pursuant to Federal Rules of Civil Procedure 23.1 and 12(b)(6). On September 19, 2014, the Ohio court granted defendants’ motion to transfer *North* to Delaware. Following that decision and in light of that transfer, on September 29, 2014, the Delaware court denied without prejudice defendants’ motion to dismiss *KBC,* and referred both cases to Magistrate Judge Burke. Defendants intend to renew their motion to dismiss the claims and allegations in KBC once it has been determined how these two cases are to proceed. On October 15, 2014, the plaintiff in *KBC* filed a motion seeking to consolidate *KBC* and *North*, to have plaintiff *KBC* appointed the sole lead plaintiff and its counsel, Motley Rice, sole lead counsel, and to designate *KBC* the sole operative complaint. Plaintiff North has indicated that she does not oppose consolidation of the two cases, but otherwise opposes *KBC’s* motion with regard to the appointment of lead plaintiff and lead counsel and designation of the operative complaint. On October 20, 2014, the Court stayed Defendants’ obligation to answer, move, or otherwise respond to the complaints in KBC and North pending further order of the Court.

The Company intends to defend vigorously against the allegations in each of the above lawsuits. Regardless of the outcome of any of the preceding matters, responding to the subpoenas and dealing with the various regulatory agencies and opposing parties can adversely affect us through defense costs, potential payments, diversion of management time, and related publicity. Although the Company intends to defend them vigorously, there can be no assurance that those suits will not have a material adverse effect on the Company.

-18-

### Results of Operations

### Three months ended September 30, 2014 versus 2013 - Consolidated Results

Our service revenues and sales for the third quarter of 2014 increased 5.1% versus services and sales revenues for the third quarter of 2013. Of this increase, $11.4 million was attributable to VITAS and a $6.1 million increase at Roto-Rooter. The following chart shows the components of those changes (in thousands):

| VITAS | Increase/(Decrease) Amount | Percent |
| --- | ---: | ---: |
| Routine homecare | $8,489 | 4.3 |
| Continuous care | 2,027 | 5.6 |
| General inpatient | 188 | 0.8 |
| Medicare cap | 679 | 21.4 |
| Roto-Rooter |  |  |
| Plumbing | 996 | 2.5 |
| Drain cleaning | 92 | 0.3 |
| Contractor operations | 697 | 8.7 |
| Other | 4,335 | 70.0 |
| Total | $17,503 | 5.1 |

The increase in VITAS’ revenues for the third quarter of 2014 versus the third quarter of 2013 was a combination of Medicare reimbursement rates increasing approximately 1.4% and a 2.8% increase in ADC. In the third quarter of 2014, VITAS recorded a net revenue reduction of $2.5 million related to the recording of Medicare Cap liability for two programs’ 2014 Medicare cap billing limitation which compares to a revenue reduction of $3.2 million in the same quarter of 2013. The ADC increase was driven by a 2.8% increase in routine homecare and a 3.8% increase in continuous care. Over 90% of VITAS’ service revenues for the period were from Medicare and Medicaid.

The increase in plumbing revenues for the third quarter of 2014 versus 2013 is attributable to a 3.6% decrease in job count, offset by a 6.3% increase in a combination of price and service mix shift. Drain cleaning revenues for the third quarter of 2014 versus 2013 reflect a 3.9% decrease in the number of jobs performed, offset by a 4.2% increase in a combination of price and service mix shift. Other Roto-Rooter revenue increased 70.0% mainly as a result of an increase in our water restoration line of business. Water restoration is the remediation of water and humidity damage after a flood.

The consolidated gross margin was 28.4% in the third quarter of 2014 as compared with 28.7% in the third quarter of 2013. On a segment basis, VITAS’ gross margin was 22.0% in the third quarter of 2014 and 22.3% in the third quarter of 2013. The Roto-Rooter segment’s gross margin was 46.9% for the third quarter of 2014 as compared with 47.3% for the third quarter of 2013.

Selling, general and administrative expenses (“SG&A”) comprise (in thousands):

| SG&A expenses before the impact of market gains/(losses) of deferred compensation | Three months ended September 30, 2014 | 2013 |
| --- | ---: | ---: |
| plans, long-term incentive compensation, and OIG investigation expenses | **$51,218** | $49,595 |
| Long-term incentive compensation | **1,002** | 55 |
| Net expenses/(cost recovery) related to OIG investigation | **450** | (591) |
| Market value gains/(losses) related to assets held in deferred compensation |  |  |
| trusts | **896** | (189) |
| Total SG&A expenses | **$53,566** | $48,870 |

SG&A expenses before long-term incentive compensation, expenses related to OIG investigation and the impact of market gains of deferred compensation plans for the third quarter of 2014 were up 3.3% when compared to the third quarter of 2013 as a result of normal salary increases and favorable insurance accrual adjustments in 2013.

-19-

Other operating expenses decreased $11.5 million in the third quarter of 2014 when compared to the third quarter of 2013 as a result of lawsuit settlements at Vitas and Roto-Rooter in 2013 that did not repeat in 2014.

Other income - net comprise (in thousands):

| Market value gains/(losses) on assets held in | Three months ended September 30, 2014 | 2013 |
| --- | ---: | ---: |
| deferred compensation trusts | **$896** | $(189) |
| Loss on disposal of property and equipment | **(167)** | (101) |
| Interest income - net | **(13)** | 192 |
| Other | **(11)** | 8 |
| Total other income - net | **$705** | $(90) |

Our effective income tax rate was 38.4% in the third quarter of 2014 compared to 32.0% for the third quarter of 2013. This is a result of a $1.8 million credit recorded in the third quarter of 2013 related to the expiration of tax statutes for uncertain tax positions recorded in prior years that did not recur in 2014.

Net income for both periods included the following after-tax items/adjustments that reduced or increased after-tax earnings (in thousands):

| VITAS | Three months ended September 30, 2014 | 2013 |
| --- | ---: | ---: |
| Litigation settlements | **$-** | $(6,510) |
| Net cost recovery/(expenses) related to OIG investigation | **(279)** | 367 |
| Acquisition expenses | **-** | (11) |
| Roto-Rooter |  |  |
| Net recoveries related to litigation settlements | **143** | - |
| Litigation settlements | **-** | (584) |
| Expenses related to litigation settlements | **-** | (269) |
| Acquisition expenses | **-** | (1) |
| Corporate |  |  |
| Stock option expense | **(615)** | (1,030) |
| Noncash impact of change in accounting for convertible debt | **-** | (1,375) |
| Uncertain tax position adjustments | **-** | 1,782 |
| Long-term incentive compensation | **(634)** | (34) |
| Expenses related to securities litigation | **(88)** | (1) |
| Total | **$(1,473)** | $(7,666) |

### Three months ended September 30, 2014 versus 2013 - Segment Results

The change in after-tax earnings for the third quarter of 2014 versus the third quarter of 2013 is due to (in thousands):

|  | Increase/(Decrease) Amount | Percent |
| --- | ---: | ---: |
| VITAS | $6,985 | 47.8 |
| Roto-Rooter | 1,667 | 20.4 |
| Corporate | (1,499) | (28.0) |
|  | $7,153 | 41.0 |

-20-

### Results of Operations

### Nine months ended September 30, 2014 versus 2013 - Consolidated Results

Our service revenues and sales for the first nine months of 2014 increased 1.1% versus services and sales revenues for the first nine months of 2013. Of this increase, $926,000 was attributable to VITAS and an $11.2 million increase at Roto-Rooter. The following chart shows the components of those changes (in thousands):

| VITAS | Increase/(Decrease) Amount | Percent |
| --- | ---: | ---: |
| Routine homecare | $7,370 | 1.2 |
| Continuous care | (5,665) | (4.7) |
| General inpatient | (2,144) | (2.7) |
| Medicare cap | 1,365 | 43.2 |
| Roto-Rooter |  |  |
| Plumbing | 3,687 | 2.9 |
| Drain cleaning | (2,336) | (2.2) |
| Contractor operations | 2,546 | 10.4 |
| Other | 7,323 | 39.3 |
| Total | $12,146 | 1.1 |

The increase in VITAS’ revenues for the first nine months of 2014 versus the first nine months of 2013 was a combination of Medicare reimbursement rates increasing approximately 1.4%, offset by a 2.0% decline due to sequestration (which was effective May 1, 2013), an ADC increase of 0.3%, and geographical and level of care mix shift. In the first nine months of 2014, VITAS recorded a revenue adjustment of $1.8 million related to eliminating the Medicare cap billing limitation recorded in the fourth quarter of 2013 for one program and by the recording of Medicare cap billing limitations for two programs’ liability for the 2014 Medicare cap year. This compares with a $3.2 million Medicare cap liability recorded in the first nine months of 2013. The ADC increase was driven by a 0.7% increase in routine homecare, a decrease of 5.3% in continuous care and a decrease of 2.5% in general inpatient. Over 90% of VITAS’ service revenues for the period were from Medicare and Medicaid.

The increase in plumbing revenues for the first nine months of 2014 versus 2013 is attributable to a 1.1% increase in job count, and a 1.8% increase in price and service mix shift. Drain cleaning revenues for the first nine months of 2014 versus 2013 reflect a 6.5% decrease in the number of jobs performed, offset by a 4.3% increase in a combination of price and service mix shift. Other Roto-Rooter revenue increased 39.3% as a result of a increase in our water restoration line of business. Water restoration is the remediation of water and humidity damage after a flood.

The consolidated gross margin was 28.4% in the first nine months of 2014 which is essentially flat when compared with the first nine months of 2013. On a segment basis, VITAS’ gross margin was 21.7% in the first nine months of 2014 and 21.9% in the first nine months of 2013. The Roto-Rooter segment’s gross margin was 46.7% for the first nine months of 2014 as compared with 46.9% for the first nine months of 2013.

Selling, general and administrative expenses (“SG&A”) comprise (in thousands):

| SG&A expenses before the impact of market gains of deferred compensation | Nine months ended September 30, 2014 | 2013 |
| --- | ---: | ---: |
| plans, long-term incentive compensation, and OIG investigation expenses | **$156,582** | $152,586 |
| Long-term incentive compensation | **1,988** | 1,161 |
| Expenses related to OIG investigation | **1,608** | 1,444 |
| Market value gains related to assets held in |  |  |
| deferred compensation trusts | **2,708** | 2,346 |
| Total SG&A expenses | **$162,886** | $157,537 |

-21-

SG&A expenses before long-term incentive compensation, expenses related to OIG investigation and the impact of market gains of deferred compensation plans for the first nine months of 2014 were up 2.6% when compared to the first nine months of 2013 as a result of normal salary increases and favorable insurance accrual adjustments in 2013.

Other operating expenses decreased $26.2 million in the first nine months of 2014 when compared to the first nine months of 2013 as a result of lawsuit settlements at Vitas and Roto-Rooter in 2013 that did not repeat in 2014.

Other income - net comprise (in thousands):

| Market value gains on assets held in deferred | Nine months ended September 30, 2014 | 2013 |
| --- | ---: | ---: |
| compensation trusts | **$2,708** | $2,346 |
| Loss on disposal of property and equipment | **(493)** | (180) |
| Interest income - net | **(5)** | 1,165 |
| Other | **67** | (19) |
| Total other income - net | **$2,277** | $3,312 |

Our effective income tax rate was 38.7% in the first nine months of 2014 when compared to 36.8% in the first nine months of 2013. This increase is a result of a $1.8 million credit recorded in 2013 related to the expiration of tax statutes for uncertain tax positions recorded in prior years.

Net income for both periods included the following after-tax items/adjustments that reduced or increased after-tax earnings (in thousands):

| VITAS | Nine Months Ended September 30, 2014 | 2013 |
| --- | ---: | ---: |
| Litigation settlements | **$-** | $(6,510) |
| Expenses related to litigation settlements | **(70)** | - |
| Legal expenses of OIG investigation | **(997)** | (895) |
| Acquisition expenses | **(1)** | (23) |
| Roto-Rooter |  |  |
| Net recoveries related to litigation settlements | **6** | - |
| Litigation settlements | **-** | (9,551) |
| Expenses related to litigation settlements | **-** | (699) |
| Expenses of severance arrangements | **-** | (184) |
| Acquisition expenses | **-** | (2) |
| Corporate |  |  |
| Stock option expense | **(2,159)** | (2,993) |
| Noncash impact of change in accounting for convertible debt | **(2,143)** | (4,046) |
| Uncertain tax position adjustments | **-** | 1,782 |
| Long-term incentive compensation | **(1,258)** | (734) |
| Expenses of securities litigation | **(207)** | (3) |
| Loss on extinguishment of debt | **-** | (294) |
| Total | **$(6,829)** | $(24,152) |

-22-

### Nine months ended September 30, 2014 versus 2013 - Segment Results

The change in after-tax earnings for the first nine months of 2014 versus the first nine months of 2013 is due to (in thousands):

|  | Increase/(Decrease) Amount | Percent |
| --- | ---: | ---: |
| VITAS | $5,408 | 9.8 |
| Roto-Rooter | 11,381 | 59.2 |
| Corporate | (1,585) | (7.9) |
|  | $15,204 | 28.0 |

-23-

*CHEMED CORPORATION AND SUBSIDIARY COMPANIES*

*CONSOLIDATING STATEMENT OF INCOME*

*FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2014*

*(in thousands)(unaudited)*

| 2014 (a) | VITAS | Roto-Rooter | Corporate | Chemed Consolidated |
| --- | ---: | ---: | ---: | ---: |
| Service revenues and sales | $265,384 | $93,005 | $- | $358,389 |
| Cost of services provided and goods sold | 207,105 | 49,340 | - | 256,445 |
| Selling, general and administrative expenses | 20,224 | 25,682 | 7,660 | 53,566 |
| Depreciation | 4,530 | 2,772 | 148 | 7,450 |
| Amortization | 205 | 114 | 398 | 717 |
| Total costs and expenses | 232,064 | 77,908 | 8,206 | 318,178 |
| Income/(loss) from operations | 33,320 | 15,097 | (8,206) | 40,211 |
| Interest expense | (55) | (87) | (838) | (980) |
| Intercompany interest income/(expense) | 1,660 | 760 | (2,420) | - |
| Other income/(expense)—net | (189) | (2) | 896 | 705 |
| Income/(expense) before income taxes | 34,736 | 15,768 | (10,568) | 39,936 |
| Income taxes | (13,143) | (5,920) | 3,712 | (15,351) |
| Net income/(loss) | $21,593 | $9,848 | $(6,856) | $24,585 |
| (a) The following amounts are included in net income (in thousands): |  |  |  |  |
|  |  |  |  | **Chemed** |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
| Pretax benefit/(cost): |  |  |  |  |
| Stock option expense | $- | $- | $(977) | $(977) |
| Long-term incentive compensation | - | - | (1,002) | (1,002) |
| Net recoveries related to litigation settlements | - | 234 | - | 234 |
| Expenses related to securities litigation | - | - | (138) | (138) |
| Expenses related to OIG investigation | (450) | - | - | (450) |
| Total | $(450) | $234 | $(2,117) | $(2,333) |
|  |  |  |  | **Chemed** |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
| After-tax benefit/(cost): |  |  |  |  |
| Stock option expense | $- | $- | $(615) | $(615) |
| Long-term incentive compensation | - | - | (634) | (634) |
| Net recoveries related to litigation settlements | - | 143 | - | 143 |
| Expenses related to securities litigation | - | - | (88) | (88) |
| Expenses related to OIG investigation | (279) | - | - | (279) |
| Total | $(279) | $143 | $(1,337) | $(1,473) |

-24-

*CHEMED CORPORATION AND SUBSIDIARY COMPANIES*

*CONSOLIDATING STATEMENT OF INCOME*

*FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2013*

*(in thousands)(unaudited)*

| 2013 (a) | VITAS | Roto-Rooter | Corporate | Chemed Consolidated |
| --- | ---: | ---: | ---: | ---: |
| Service revenues and sales | $254,001 | $86,885 | $- | $340,886 |
| Cost of services provided and goods sold | 197,387 | 45,797 | - | 243,184 |
| Selling, general and administrative expenses | 18,637 | 25,009 | 5,224 | 48,870 |
| Depreciation | 4,545 | 2,292 | 134 | 6,971 |
| Amortization | 538 | 151 | 501 | 1,190 |
| Other operating expenses | 10,500 | 961 | - | 11,461 |
| Total costs and expenses | 231,607 | 74,210 | 5,859 | 311,676 |
| Income/(loss) from operations | 22,394 | 12,675 | (5,859) | 29,210 |
| Interest expense | (48) | (82) | (3,370) | (3,500) |
| Intercompany interest income/(expense) | 1,231 | 579 | (1,810) | - |
| Other income/(expense)—net | 73 | 8 | (171) | (90) |
| Income/(expense) before income taxes | 23,650 | 13,180 | (11,210) | 25,620 |
| Income taxes | (9,042) | (4,999) | 5,853 | (8,188) |
| Net income/(loss) | $14,608 | $8,181 | $(5,357) | $17,432 |
| (a) The following amounts are included in net income (in thousands): |  |  |  |  |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Chemed Consolidated** |
| Pretax benefit/(cost): |  |  |  |  |
| Stock option expense | $- | $- | $(1,629) | $(1,629) |
| Noncash impact of accounting for convertible debt | - | - | (2,174) | (2,174) |
| Long-term incentive compensation | - | - | (55) | (55) |
| Litigation settlements | (10,500) | (961) | - | (11,461) |
| Expenses related to litigation settlements | - | (443) | - | (443) |
| Expenses related to securities litigation | - | - | (1) | (1) |
| Acquisition expenses | (18) | (3) | - | (21) |
| Net cost recovery related to OIG investigation | 591 | - | - | 591 |
| Total | $(9,927) | $(1,407) | $(3,859) | $(15,193) |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Chemed Consolidated** |
| After-tax benefit/(cost): |  |  |  |  |
| Stock option expense | $- | $- | $(1,030) | $(1,030) |
| Noncash impact of accounting for convertible debt | - | - | (1,375) | (1,375) |
| Long-term incentive compensation | - | - | (34) | (34) |
| Litigation settlements | (6,510) | (584) | - | (7,094) |
| Uncertain tax position adjustments | - | - | 1,782 | 1,782 |
| Expenses related to litigation settlements | - | (269) | - | (269) |
| Expenses related to securities litigation | - | - | (1) | (1) |
| Acquisition expenses | (11) | (1) | - | (12) |
| Net cost recovery related to OIG investigation | 367 | - | - | 367 |
| Total | $(6,154) | $(854) | $(658) | $(7,666) |

-25-

*CHEMED CORPORATION AND SUBSIDIARY COMPANIES*

*CONSOLIDATING STATEMENT OF INCOME*

*FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2014*

*(in thousands)(unaudited)*

| 2014 (a) | VITAS | Roto-Rooter | Corporate | Chemed Consolidated |
| --- | ---: | ---: | ---: | ---: |
| Service revenues and sales | $789,822 | $287,049 | $- | $1,076,871 |
| Cost of services provided and goods sold | 618,315 | 152,956 | - | 771,271 |
| Selling, general and administrative expenses | 62,939 | 78,569 | 21,378 | 162,886 |
| Depreciation | 13,709 | 7,732 | 430 | 21,871 |
| Amortization | 829 | 397 | 1,235 | 2,461 |
| Total costs and expenses | 695,792 | 239,654 | 23,043 | 958,489 |
| Income/(loss) from operations | 94,030 | 47,395 | (23,043) | 118,382 |
| Interest expense | (167) | (295) | (6,762) | (7,224) |
| Intercompany interest income/(expense) | 4,520 | 2,090 | (6,610) | - |
| Other income/(expense)—net | (577) | 137 | 2,717 | 2,277 |
| Income/(expense) before income taxes | 97,806 | 49,327 | (33,698) | 113,435 |
| Income taxes | (37,161) | (18,728) | 11,976 | (43,913) |
| Net income/(loss) | $60,645 | $30,599 | $(21,722) | $69,522 |
| (a) The following amounts are included in net income (in thousands): |  |  |  |  |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Chemed Consolidated** |
| Pretax benefit/(cost): |  |  |  |  |
| Stock option expense | $- | $- | $(3,430) | $(3,430) |
| Noncash impact of accounting for convertible debt | - | - | (3,389) | (3,389) |
| Long-term incentive compensation | - | - | (1,988) | (1,988) |
| Net recoveries/(expenses) related to litigation settlements | (113) | 9 | - | (104) |
| Expenses related to securities litigation | - | - | (327) | (327) |
| Acquisition expenses | (1) | - | - | (1) |
| Expenses related to OIG investigation | (1,608) | - | - | (1,608) |
| Total | $(1,722) | $9 | $(9,134) | $(10,847) |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Chemed Consolidated** |
| After-tax benefit/(cost): |  |  |  |  |
| Stock option expense | $- | $- | $(2,159) | $(2,159) |
| Noncash impact of accounting for convertible debt | - | - | (2,143) | (2,143) |
| Long-term incentive compensation | - | - | (1,258) | (1,258) |
| Net recoveries/(expenses) related to litigation settlements | (70) | 6 | - | (64) |
| Expenses related to securities litigation | - | - | (207) | (207) |
| Acquisition expenses | (1) | - | - | (1) |
| Expenses related to OIG investigation | (997) | - | - | (997) |
| Total | $(1,068) | $6 | $(5,767) | $(6,829) |

-26-

*CHEMED CORPORATION AND SUBSIDIARY COMPANIES*

*CONSOLIDATING STATEMENT OF INCOME*

*FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2013*

*(in thousands)(unaudited)*

| 2013 (a) | VITAS | Roto-Rooter | Corporate | Chemed Consolidated |
| --- | ---: | ---: | ---: | ---: |
| Service revenues and sales | $788,896 | $275,829 | $- | $1,064,725 |
| Cost of services provided and goods sold | 616,334 | 146,516 | - | 762,850 |
| Selling, general and administrative expenses | 61,304 | 76,901 | 19,332 | 157,537 |
| Depreciation | 13,579 | 6,685 | 401 | 20,665 |
| Amortization | 1,564 | 454 | 1,480 | 3,498 |
| Other operating expenses | 10,500 | 15,721 | - | 26,221 |
| Total costs and expenses | 703,281 | 246,277 | 21,213 | 970,771 |
| Income/(loss) from operations | 85,615 | 29,552 | (21,213) | 93,954 |
| Interest expense | (145) | (239) | (10,907) | (11,291) |
| Intercompany interest income/(expense) | 2,940 | 1,443 | (4,383) | - |
| Other income/(expense)—net | 878 | 42 | 2,392 | 3,312 |
| Income/(expense) before income taxes | 89,288 | 30,798 | (34,111) | 85,975 |
| Income taxes | (34,051) | (11,580) | 13,974 | (31,657) |
| Net income/(loss) | $55,237 | $19,218 | $(20,137) | $54,318 |
| (a) The following amounts are included in net income (in thousands): |  |  |  |  |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Chemed Consolidated** |
| Pretax benefit/(cost): |  |  |  |  |
| Stock option expense | $- | $- | $(4,732) | $(4,732) |
| Noncash impact of accounting for convertible debt | - | - | (6,397) | (6,397) |
| Long-term incentive compensation | - | - | (1,161) | (1,161) |
| Expenses of severance arrangements | - | (302) | - | (302) |
| Loss on extinguishment of debt | - | - | (465) | (465) |
| Litigation settlements | (10,500) | (15,721) | - | (26,221) |
| Expenses related to litigation settlements | - | (1,151) | - | (1,151) |
| Expenses related to securities litigation | - | - | (4) | (4) |
| Acquisition expenses | (38) | (4) | - | (42) |
| Expenses of OIG investigation | (1,444) | - | - | (1,444) |
| Total | $(11,982) | $(17,178) | $(12,759) | $(41,919) |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Chemed Consolidated** |
| After-tax benefit/(cost): |  |  |  |  |
| Stock option expense | $- | $- | $(2,993) | $(2,993) |
| Noncash impact of accounting for convertible debt | - | - | (4,046) | (4,046) |
| Long-term incentive compensation | - | - | (734) | (734) |
| Uncertain tax position position adjustments | - | - | 1,782 | 1,782 |
| Expenses of severance arrangements | - | (184) | - | (184) |
| Loss on extinguishment of debt | - | - | (294) | (294) |
| Litigation settlements | (6,510) | (9,551) | - | (16,061) |
| Expenses related to litigation settlements | - | (699) | - | (699) |
| Expenses related to securities litigation | - | - | (3) | (3) |
| Acquisition expenses | (23) | (2) | - | (25) |
| Expenses of OIG investigation | (895) | - | - | (895) |
| Total | $(7,428) | $(10,436) | $(6,288) | $(24,152) |

-27-

*Unaudited Consolidating Summary and Reconciliation of Adjusted EBITDA*

*(in thousands)*

| Chemed Corporation and Subsidiary Companies For the three months ended September 30, 2014 | VITAS | Roto-Rooter | Corporate | Chemed Consolidated |
| --- | ---: | ---: | ---: | ---: |
| **Net income/(loss)** | $21,593 | $9,848 | $(6,856) | $24,585 |
| Add/(deduct): |  |  | - |  |
| Interest expense | 55 | 87 | 838 | 980 |
| Income taxes | 13,143 | 5,920 | (3,712) | 15,351 |
| Depreciation | 4,530 | 2,772 | 148 | 7,450 |
| Amortization | 205 | 114 | 398 | 717 |
| **EBITDA** | 39,526 | 18,741 | (9,184) | 49,083 |
| Add/(deduct): |  |  |  |  |
| Intercompany interest expense/(income) | (1,660) | (760) | 2,420 | - |
| Interest income | 23 | (9) | (1) | 13 |
| Expenses related to OIG investigation | 450 | - | - | 450 |
| Net recoveries related to litigation settlements | - | (234) | - | (234) |
| Advertising cost adjustment | - | (483) | - | (483) |
| Stock option expense | - | - | 977 | 977 |
| Long-term incentive compensation | - | - | 1,002 | 1,002 |
| Expenses related to securities litigation | - | - | 138 | 138 |
| **Adjusted EBITDA** | $38,339 | $17,255 | $(4,648) | $50,946 |
| For the three months ended September 30, 2013 | **VITAS** | **Roto-Rooter** | **Corporate** | **Chemed Consolidated** |
| **Net income/(loss)** | $14,608 | $8,181 | $(5,357) | $17,432 |
| Add/(deduct): |  |  |  |  |
| Interest expense | 48 | 82 | 3,370 | 3,500 |
| Income taxes | 9,042 | 4,999 | (5,853) | 8,188 |
| Depreciation | 4,545 | 2,292 | 134 | 6,971 |
| Amortization | 538 | 151 | 501 | 1,190 |
| **EBITDA** | 28,781 | 15,705 | (7,205) | 37,281 |
| Add/(deduct): |  |  |  |  |
| Intercompany interest expense/(income) | (1,231) | (579) | 1,810 | - |
| Interest income | (163) | (10) | (19) | (192) |
| Expenses related to OIG investigation | (591) | - | - | (591) |
| Acquisition expenses | 18 | 3 | - | 21 |
| Litigation settlements | 10,500 | 961 | - | 11,461 |
| Advertising cost adjustment | - | (369) | - | (369) |
| Expenses related to litigation settlements | - | 443 | - | 443 |
| Long-term incentive compensation | - | - | 55 | 55 |
| Stock option expense | - | - | 1,629 | 1,629 |
| Expenses of securities litigation | - | - | 1 | 1 |
| **Adjusted EBITDA** | $37,314 | $16,154 | $(3,729) | $49,739 |

-28-

*Unaudited Consolidating Summary and Reconciliation of Adjusted EBITDA*

*(in thousands)*

| Chemed Corporation and Subsidiary Companies For the nine months ended September 30, 2014 | VITAS | Roto-Rooter | Corporate | Chemed Consolidated |
| --- | ---: | ---: | ---: | ---: |
| **Net income/(loss)** | $60,645 | $30,599 | $(21,722) | $69,522 |
| Add/(deduct): |  |  |  |  |
| Interest expense | 167 | 295 | 6,762 | 7,224 |
| Income taxes | 37,161 | 18,728 | (11,976) | 43,913 |
| Depreciation | 13,709 | 7,732 | 430 | 21,871 |
| Amortization | 829 | 397 | 1,235 | 2,461 |
| **EBITDA** | 112,511 | 57,751 | (25,271) | 144,991 |
| Add/(deduct): |  |  |  |  |
| Intercompany interest expense/(income) | (4,520) | (2,090) | 6,610 | - |
| Interest income | 43 | (28) | (10) | 5 |
| Expenses related to OIG investigation | 1,608 | - | - | 1,608 |
| Acquisition expenses | 1 | - | - | 1 |
| Net expenses/(recoveries) related to litigation settlements | 113 | (9) | - | 104 |
| Advertising cost adjustment | - | (1,623) | - | (1,623) |
| Stock option expense | - | - | 3,430 | 3,430 |
| Long-term incentive compensation | - | - | 1,988 | 1,988 |
| Expenses related to securities litigation | - | - | 327 | 327 |
| **Adjusted EBITDA** | $109,756 | $54,001 | $(12,926) | $150,831 |
|  |  |  |  | **Chemed** |
| For the nine months ended September 30, 2013 | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
| **Net income/(loss)** | $55,237 | $19,218 | $(20,137) | $54,318 |
| Add/(deduct): |  |  |  |  |
| Interest expense | 145 | 239 | 10,907 | 11,291 |
| Income taxes | 34,051 | 11,580 | (13,974) | 31,657 |
| Depreciation | 13,579 | 6,685 | 401 | 20,665 |
| Amortization | 1,564 | 454 | 1,480 | 3,498 |
| **EBITDA** | 104,576 | 38,176 | (21,323) | 121,429 |
| Add/(deduct): |  |  |  |  |
| Intercompany interest expense/(income) | (2,940) | (1,443) | 4,383 | - |
| Interest income | (1,051) | (66) | (48) | (1,165) |
| Expenses related to OIG investigation | 1,444 | - | - | 1,444 |
| Acquisition expenses | 38 | 4 | - | 42 |
| Litigation settlement | 10,500 | 15,721 | - | 26,221 |
| Advertising cost adjustment | - | (1,343) | - | (1,343) |
| Cost of severance arrangements | - | 302 | - | 302 |
| Expenses related to litigation settlements | - | 1,151 | - | 1,151 |
| Long-term incentive compensation | - | - | 1,161 | 1,161 |
| Stock option expense | - | - | 4,732 | 4,732 |
| Expenses related to securities litigation | - | - | 4 | 4 |
| **Adjusted EBITDA** | $112,567 | $52,502 | $(11,091) | $153,978 |

-29-

*CHEMED CORPORATION AND SUBSIDIARY COMPANIES*

*RECONCILIATION OF ADJUSTED NET INCOME*

*(in thousands, except per share data)(unaudited)*

|  | Three Months Ended September 30, 2014 | 2013 | Nine Months Ended September 30, 2014 | 2013 |
| --- | ---: | ---: | ---: | ---: |
| Net income as reported | **$24,585** | $17,432 | **$69,522** | $54,318 |
| Add/(deduct) after-tax cost of: |  |  |  |  |
| Net expenses/(recoveries) related to litigation settlements | **(143)** | 269 | **64** | 699 |
| Uncertain tax position adjustments | **-** | (1,782) | **-** | (1,782) |
| Additional interest expense resulting from the change in accounting |  |  |  |  |
| for the conversion feature of the convertible notes | **-** | 1,375 | **2,143** | 4,046 |
| Stock option expense | **615** | 1,030 | **2,159** | 2,993 |
| Net expenses/(cost recovery) of OIG investigation | **279** | (367) | **997** | 895 |
| Long-term incentive compensation | **634** | 34 | **1,258** | 734 |
| Litigation settlements | **-** | 7,094 | **-** | 16,061 |
| Acquisition expenses | **-** | 12 | **1** | 25 |
| Loss on extinguishment of debt | **-** | - | **-** | 294 |
| Expenses of severance arrangements | **-** | - | **-** | 184 |
| Expenses related to securities litigation | **88** | 1 | **207** | 3 |
| Adjusted net income | **$26,058** | $25,098 | **$76,351** | $78,470 |
| Diluted Earnings Per Share As Reported |  |  |  |  |
| Net income | **$1.39** | $0.94 | **$3.87** | $2.89 |
| Average number of shares outstanding | **17,627** | 18,522 | **17,968** | 18,824 |
| Adjusted Diluted Earnings Per Share |  |  |  |  |
| Adjusted net income | **$1.48** | $1.36 | **$4.28** | $4.17 |
| Adjusted average number of shares outstanding\* | **17,627** | 18,522 | **17,833** | 18,824 |

\* Adjusted diluted average shares outstanding excludes the estimated dilutive impact of the Convertible Notes prior to conversion of these Notes on May 15, 2014 (135,000 shares for the nine months ended September 30, 2014) as this impact was entirely offset upon the exercise of the note hedges on May 15, 2014.

-30-

*CHEMED CORPORATION AND SUBSIDIARY COMPANIES*

*OPERATING STATISTICS FOR VITAS SEGMENT*

*(unaudited)*

| OPERATING STATISTICS Net revenue ($000) | Three Months Ended September 30, 2014 | 2013 | Nine Months Ended September 30, 2014 | 2013 |
| --- | ---: | ---: | ---: | ---: |
| Homecare | **$204,965** | $196,476 | **$600,780** | $593,410 |
| Inpatient | **25,012** | 24,824 | **77,037** | 79,181 |
| Continuous care | **37,907** | 35,880 | **113,801** | 119,466 |
| Total before Medicare cap allowance | **$267,884** | $257,180 | **$791,618** | $792,057 |
| Medicare cap allowance | **(2,500)** | (3,179) | **(1,796)** | (3,161) |
| Total | **$265,384** | $254,001 | **$789,822** | $788,896 |
| Net revenue as a percent of total before Medicare cap allowances |  |  |  |  |
| Homecare | **76.5%** | 76.4% | **75.9%** | 74.9% |
| Inpatient | **9.3** | 9.7 | **9.7** | 10.0 |
| Continuous care | **14.2** | 14.0 | **14.5** | 15.2 |
| Total before Medicare cap allowance | **100.0** | 100.1 | **100.1** | 100.1 |
| Medicare cap allowance | **(0.9)** | (1.3) | **(0.2)** | (0.4) |
| Total | **99.1%** | 98.8% | **99.9%** | 99.7% |
| Average daily census (days) |  |  |  |  |
| Homecare | **10,662** | 10,373 | **10,562** | 10,482 |
| Nursing home | **2,999** | 2,911 | **2,940** | 2,928 |
| Routine homecare | **13,661** | 13,284 | **13,502** | 13,410 |
| Inpatient | **417** | 417 | **429** | 440 |
| Continuous care | **561** | 540 | **568** | 600 |
| Total | **14,639** | 14,241 | **14,499** | 14,450 |
| Total Admissions | **15,653** | 14,555 | **47,777** | 47,413 |
| Total Discharges | **15,460** | 14,971 | **47,139** | 47,603 |
| Average length of stay (days) | **83.7** | 82.2 | **82.4** | 81.3 |
| Median length of stay (days) | **15.0** | 16.0 | **15.0** | 15.0 |
| ADC by major diagnosis |  |  |  |  |
| Neurological | **32.7%** | 37.8% | **35.0%** | 36.8% |
| Cancer | **17.3** | 17.1 | **17.4** | 17.0 |
| Cardio | **17.6** | 13.9 | **16.6** | 12.8 |
| Respiratory | **8.0** | 7.8 | **7.9** | 7.5 |
| Other | **24.4** | 23.4 | **23.1** | 25.9 |
| Total | **100.0%** | 100.0% | **100.0%** | 100.0% |
| Admissions by major diagnosis |  |  |  |  |
| Neurological | **18.2** | 21.0% | **20.6%** | 20.3% |
| Cancer | **34.0** | 34.4 | **33.3** | 33.0 |
| Cardio | **15.2** | 13.8 | **14.8** | 13.0 |
| Respiratory | **9.1** | 9.0 | **9.5** | 9.3 |
| Other | **23.5** | 21.8 | **21.8** | 24.4 |
| Total | **100.0%** | 100.0% | **100.0%** | 100.0% |
| Direct patient care margins |  |  |  |  |
| Routine homecare | **53.8%** | 52.5% | **53.4%** | 52.2% |
| Inpatient | **4.9** | 1.7 | **5.4** | 5.6 |
| Continuous care | **17.4** | 14.8 | **17.2** | 15.8 |
| Homecare margin drivers (dollars per patient day) |  |  |  |  |
| Labor costs | **$53.65** | $54.64 | **$54.31** | $55.61 |
| Drug costs | **6.64** | 7.52 | **7.04** | 7.55 |
| Home medical equipment | **6.09** | 6.67 | **6.07** | 6.69 |
| Medical supplies | **3.22** | 2.83 | **3.20** | 2.96 |
| Inpatient margin drivers (dollars per patient day) |  |  |  |  |
| Labor costs | **$345.18** | $354.09 | **$344.05** | $339.84 |
| Continuous care margin drivers (dollars per patient day) |  |  |  |  |
| Labor costs | **$584.99** | $594.25 | **$586.60** | $592.15 |
| Bad debt expense as a percent of revenues | **1.0%** | 0.9% | **1.0%** | 0.9% |
| Accounts receivable -- |  |  |  |  |
| Days of revenue outstanding- excluding unapplied Medicare payments | **38.1** | 34.6 | **n.a** | n.a |
| Days of revenue outstanding- including unapplied Medicare payments | **36.3** | 21.9 | **n.a** | n.a |

-31-

### Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 Regarding Forward-Looking Information

Certain statements contained in this report are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe”, “expect”, “hope”, “anticipate”, “plan” and similar expressions identify forward-looking statements, which speak only as of the date the statement was made. These forward-looking statements are based on current expectations and assumptions and involve various known and unknown risks, uncertainties, contingencies and other factors, which could cause Chemed’s actual results to differ from those expressed in such forward-looking statements. Variances in any or all of the risks, uncertainties, contingencies, and other factors from our assumptions could cause actual results to differ materially from these forward-looking statements and trends. In addition, our ability to deal with the unknown outcomes of these events, many of which are beyond our control, may affect the reliability of projections and other financial matters. Investors are cautioned that such forward-looking statements are subject to inherent risk and there are no assurances that the matters contained in such statements will be achieved. Chemed does not undertake and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of a new information, future events or otherwise.

## Market risk

As filed, 605 characters.

The Company’s primary market risk exposure relates to interest rate risk exposure through its variable interest line of credit. At September 30, 2014, the Company had $173.6 million of variable rate debt outstanding. For each $10 million dollars borrowed under the credit facility, an increase or decrease of 100 basis points (1% point), increases or decreases the Company’s annual interest expense by $100,000.

The Company continually evaluates this interest rate exposure and periodically weighs the cost versus the benefit of fixing the variable interest rates through a variety of hedging techniques.

## Controls and procedures

As filed, 900 characters.

We carried out an evaluation, under the supervision of our President and Chief Executive Officer and with the participation of the Executive Vice President and Chief Financial Officer and the Vice President and Controller, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, the President and Chief Executive Officer, Executive Vice President and Chief Financial Officer and Vice President and Controller have concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report. There has been no change in our internal control over financial reporting that occurred during the quarter covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 141 characters.

There have been no material changes from the risk factors previously disclosed in the Company’s most recent Annual Report on Form 10-K.

-32-

Filed Nov 5, 2014.
Source: SEC EDGAR, the filing index for accession 0001157523-14-004380. Last ingested by Listed: Nov 14, 2026, 12:29 ET. No prices; not investment advice.
